How it Works
Watch how the Esprit™ BTK System can treat BTK (below-the-knee) lesions using a bioresorbable scaffold that addresses vessel recoil and dissection4, combined with a drug that inhibits neointimal hyperplasia6, and then fully resorbs over time1, preserving future treatment options.
The PLLA resorbable scaffold supports the treated artery to address vessel recoil and dissection1, while the sustained everolimus elution inhibits restenosis and maximizes patency2. Ultimately the scaffold is completely resorbed*,2, leaving nothing behind.
Esprit™ BTK System resorption timeline
After the scaffold has been implanted and delivers the drug into the vessel, it begins to resorb naturally and disappear into the body over time like dissolving stitches, with complete resorption.2*
Representative photomicrographs of porcine coronary arteries implanted with Absorb BVS (1–48 months). Data on file at Abbott.
*Excluding platinum markers.
References
- Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU).
- Data on file at Abbott.
- Data on file at Abbott. Testing done with XIENCE Sierra™ 3.5 x 38 mm at nominal.
MAT-2408195 v1.0